Meeting glycemic targets is a challenging task in young patients with T1D; thus, new insulin delivery systems represent an opportunity to improve glycemic control, to promote patient-centered decisions, and to reduce the burden of diabetes care [4, 5]. The gene discussed is INS; the disease is diabetes mellitus.